<?xml version="1.0" encoding="UTF-8"?>
<p>Opioid agonist medications for OUD, methadone and buprenorphine, reduce all-cause mortality by as much as fifty percent and are associated with positive changes in a number of other outcomes including reductions in overdose, resumed use, and HIV infections.
 <sup>
  <xref rid="R4" ref-type="bibr">4</xref>
 </sup> Naloxone, a relatively inexpensive and extremely effective pharmaceutical antidote to opioid overdose, has been distributed in the community for decades, where it is associated with reductions in opioid overdose deaths.
 <sup>
  <xref rid="R5" ref-type="bibr">5</xref>
 </sup> Finally, the provision of sterile syringes dramatically reduces the risk of bloodborne disease transmission related to sharing syringes for intravenous opioid use, and syringe services programs effectively link individuals with OUD to evidence-based treatment.
 <sup>
  <xref rid="R6" ref-type="bibr">6</xref>
 </sup>
</p>
